Table 1.
Characteristics of early stage patients
| Characteristic | N = 487 | |
|---|---|---|
| Age | Median (range) | 60 (9–92) |
| Gender | ||
| Female | 277 (57%) | |
| Male | 210 (43%) | |
| Stage | ||
| I | 434 (89%) | |
| II | 53 (11%) | |
| Primary site at diagnosis | ||
| Stomach | 155 (32%) | |
| Orbit | 68 (14%) | |
| Lung | 60 (12%) | |
| Skin | 61 (13%) | |
| Head and neck | 26 (5%) | |
| Thyroid | 9 (2%) | |
| Other | 108 (22%) | |
| IPI risk group | ||
| Unknown | 2 (0%) | |
| Low risk (0–1 points) | 461 (95%) | |
| Low-intermediate risk (2 points) | 24 (5%) | |
| B-symptoms at diagnosis | ||
| Not present | 463 (95%) | |
| Present | 18 (4%) | |
| N/A | 6 (1%) | |
| Initial treatment type | ||
| Surgery | 144 (30%) | |
| Chemotherapy | 9 (2%) | |
| Radiation therapy | 244 (50%) | |
| Chemotherapy and RTa | 2 (0%) | |
| Immunotherapy | 19 (4%) | |
| Observation | 39 (8%) | |
| Other | 30 (6%) | |
| Sites at diagnosis | ||
| >1 site | 37 (8%) | |
| 1 site | 450 (92%) | |
| Bone marrow biopsy | ||
| Not done or N/A | 222 (46%) | |
| Negative | 265 (54%) | |
| Among patients receiving RT as initial treatment (N = 246)b | ||
| RT dose | ||
| <3000 | 42 (17%) | |
| 3000 | 157 (64%) | |
| >3000 | 37 (15%) | |
| Unknown dose | 10 (4%) | |
Percentages may not add up to 100 due to rounding.
a
Grouped with RT for analysis.
b
Includes ChemoRT as initial treatment.
IPI, International Prognostic Index; RT, radiotherapy.